linzess- linaclotide capsule, gelatin coated
allergan, inc. - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug - linzess is indicated for the treatment of: • irritable bowel syndrome with constipation (ibs-c) in adults • chronic idiopathic constipation (cic) in adults • functional constipation (fc) in pediatric patients 6 to 17 years of age linzess is contraindicated in: - patients less than 2 years of age due to the risk of serious dehydration [see warnings and precautions ( 5.1 ), use in specific populations ( 8.4 )] . - patients with known or suspected mechanical gastrointestinal obstruction. risk summary linaclotide and its active metabolite are negligibly absorbed systemically following oral administration [see clinical pharmacology ( 12.3 )] , and maternal use is not expected to result in fetal exposure to the drug. the available data on linzess use in pregnant women are not sufficient to inform any drug-associated risk for major birth defects and miscarriage. in animal developmental studies, no effects on embryo-fetal development were observed with oral administration of linaclotide in rats and rabbits during o
linzess linaclotide capsule gelatin coated
lake erie medical dba quality care products llc - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug
linzess linaclotide capsule gelatin coated
avera mckennan hospital - linaclotide (unii: n0txr0xr5x) (linaclotide - unii:n0txr0xr5x) - linaclotide 145 ug
linaclotide 290microgram capsules
ennogen healthcare ltd - linaclotide - oral capsule - 290microgram
constella
abbvie deutschland gmbh & co. kg - linaclotide - irritable bowel syndrome - drugs for constipation - constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (ibs-c) in adults.
constella capsule
abbvie corporation - linaclotide - capsule - 145mcg - linaclotide 145mcg - miscellaneous gi drugs
constella capsule
abbvie corporation - linaclotide - capsule - 290mcg - linaclotide 290mcg - miscellaneous gi drugs
constella capsule
abbvie corporation - linaclotide - capsule - 72mcg - linaclotide 72mcg - miscellaneous gi drugs
constella linaclotide 290 microgram hard capsule bottle
abbvie pty ltd - linaclotide, quantity: 0.29 mg - capsule, hard - excipient ingredients: calcium chloride dihydrate; hypromellose; microcrystalline cellulose; leucine; titanium dioxide; potable water; gelatin; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; shellac; sulfuric acid - constella is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (ibs-c) and ? chronic idiopathic constipation (cic) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.
constella linaclotide 145 microgram hard capsule bottle
abbvie pty ltd - linaclotide, quantity: 0.145 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; calcium chloride dihydrate; leucine; hypromellose; titanium dioxide; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; shellac; sulfuric acid - constella is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (ibs-c) and ? chronic idiopathic constipation (cic) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.